Yazar "Çakmak, Hüseyin Altuğ" için listeleme
-
Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)
Ekici, Berkay; Yaman, Mehmet; Küçük, Murathan; Dereli, Seçkin; Yenerçağ, Mustafa; Yiğit, Zerrin; Baş, Mehmet Memduh; Karavelioğlu, Yusuf; Çakmak, Hüseyin Altuğ; Kıvrak, Tarık; Özkan, Hakan; Altın, Cihan; Şabanoğlu, Cengiz; Demirkan, Burcu; Ataş, Ali Ekber; Kılıçaslan, Fethi; Altay, Hakan; Tengiz, İstemihan; Erkan, Aycan Fahri; Kılıçaslan, Barış; Olgun, Fatih Erkam; Durakoğlugil, Murtaza Emre; Alhan, Aslıhan; Zoghi, Mehdi (AVES, 2021)Objective: Heart failure (HF) is a growing public health problem with high morbidity and mortality. Recently, angiotensin receptor neprilysin inhibitor (ARNi) has emerged as a promising treatment for HF with reduced ejection ... -
New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study
Altay, Servet; Yıldırımtürk, Özlem; Çakmak, Hüseyin Altuğ; Aşkın, Lütfü; Sinan, Ümit Yaşar; Beşli, Feyzullah; Gedikli, Ömer; Tok, Özge Özden; Karadeniz, Fatma Özpamuk; Ünlü, Serkan; Yanık, Ahmet; Uçar, Fatih Mehmet; Duman, Hakan; Canpolat, Uğur; Koroğlu, Bayram; Yayla, Çağrı; Özcan, Kazım Serhan; Velibey, Yalçın; Gülel, Okan; Kalkan, Mehmet Emin; Karaca, Gürkan; Akboğa, Mehmet Kadri; Akdağ, Serkan; Eren, Mehmet; Şahin, Mahmut; Pehlivanoğlu, Seçkin (Turkish Soc Cardiology, 2017)Objective: New oral anticoagulants (NOACs) are increasingly used both for prevention of stroke in non-valvular atrial fibrillation (NVAF) and the treatment of venous thromboembolism (VTE). in this study, we aimed to evaluate ...
